Week 9 part 1 Flashcards

1
Q

What are neurodegenerative disorder characterised by?

A

Progressive loss of neuronal structure and function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are neurodegenerative disorders?

A

Diverse in their pathophysiology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is an example of pathophysiology?

A

Heterogenous clinical and pathological expression affect specific subset of neurons in specific-functional anatomic systems

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are parkinson’s disease characterised by?

A
  1. Resting Tremor
  2. Slowness of movement (bradykinesia)
  3. Muscular rigidity
  4. Postural instability
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are defects in motor function due to?

A

loss of dopaminergic neurons in the substantia nigra pars compacta

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is substantia nigra?

A

Strips of cells which contain neuromelanin

Very dark pigment

dopaminergic cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What do neurodegenerative disorder rise dramatically with?

A

Age

Numbers are expected to increase due to increasing life expectancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are Huntington disease characterised by?

A
  1. Involuntary movements
  2. Mood alterations e.g. depression
  3. Personality alterations e.g. irritability, impulsive or eccentric behavioyr
  4. Defect in memory and attention
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the pathology of Huntington disease?

A
  1. striatal atrophy: loss of medium spiny neurons

2. Cortical atrophy: loss of cortical pyramidal neurons (CPNs) in motor and premotor area

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are defects in motor function of HD pathology?

A
  1. loss of GABAergic neurons in corpus stratium

2. Enlargement of ventricles and shrinkage of basal ganglia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are limitations to brain bank material?

A
  1. Pathological changes are only revealed post-mortem
  2. Earliest changes in neurodegenerative disorders are missed
  3. End-stage tissue is depleted of neurons
  4. Post-mortem delay affects protein e.g. stability
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What can biomarkers reflecting different types of pathophysiology be viewed as?

A
  1. Clinical diagnosis
  2. Predict and monitor disease progression
  3. Monitoring effects of novel drug candidates in clinical trials
  4. Clinical research into the pathogenesis of disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are biomarkers that allow for pre-symptomatic detection crucial for

A

Faciliate the development of an efficient and rapid treatment as early as possible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are Alzheimer’s disease characterised by?

A
  1. Defects in memory
  2. Cognitive decline
  3. Confusion and disorientation
  4. Changes in mood and personality
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are 2 two pathological hallmark of AD?

A
  1. Amyloid plaques

2. Tau - Neurofibril tangles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What do amyloid plaque and Tau have?

A

Specific pattern of deposition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Where are amyloid plaques in?

A

Medial and frontal temporal lobe before the burden increases

Area which amyloid deposits increases in the cortex

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Where is Tau located in?

A

Hippocampus

Before spreading to the frontal love and over the cortex

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What are Amyloid plaques?

A

Extracellular accumulations prinicipally composed of abnormally folded amylod beta with 40-42 amino acids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What are two by-products of APP metabolism?

A
  1. Ab40

2. Ab42

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is more abundant within plaques?

A

Ab40

Due to higher rate of fibrillisation and insolubility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is APP cleaved by?

A

beta-gamma secretase which leads to formation of ab peptide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is Tau?

A
  1. Microtubule-associated protein
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What does Tau have a role in?

A
  1. Microtubule stabilisation

2. Axonal transport

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What does hyperphosphorylation of Tau result in?

A

Formation of neurofibrillary tangles

which are composed of paired helical filaments (PHF) of Tau

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What are the 3 areas where most biomarkers are focused on?

A
  1. Plaques
  2. Tangles of Tau
  3. Neuronal degeneration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

When is clinical diagnosis of dementia made?

A

Biomarkers follow this time pattern and when enough change in brain structure happens

28
Q

What is considered in terms of gene base biomarkers?

A

target amyloid and tau progression early on or even better trying to target before

29
Q

What does the cerebrospinal fluid occupy?

A
  1. Ventricular system

2. Cranial and spinal subarachnoid space

30
Q

What does CSF acts as?

A

Liquid cushion providing basic mechanical and immunological protection

31
Q

What is CSF?

A

most informative fluid in biomarker discovery for neurodegenerative disorders.

32
Q

What does CSF have?

A

more physical contact with brain than any other fluid, as it is not separated from the brain by the blood brain barrier (BBB)

33
Q

What most likely diffuse into CSF than into any other bodily fluid?

A

proteins or peptides that may be directly reflective of brain specific activities as well as disease pathology

34
Q

How can we categorise CSF biomarkers?

A
  1. the core csf biomarkers and theres 3 of them

2. theres more novel biomarkers that need more verification and validation

35
Q

What it is total Tau?

A

Not AD specific

36
Q

What is counter intuitive?

A

♣ ab42 and ab42/40 ratio

37
Q

What us lowered ub CSF?

A

increase in CSF of amyloid ab42 and ab42/40 ratio

38
Q

What is the main test for CSF amyloid 42 and the ratio of 42-40?

A

Elisa

39
Q

What is a problem with Elisa?

A

variation between research groups and organizations

40
Q

What are core CSF biomarkers ?

A

Well-validated for neurodegeneration as well as amyloid plaque and tau tangle pathology

41
Q

What are there no validated biomarkers for?

A

Synaptic dysfunction

42
Q

What is biomarkers for synaptic dysfunction?

A

Best pathoanatomical correlates of cognitive deficit and predicts disease better than amyloid plaque load

43
Q

What would be a valuable addition to Alzheimer’s disease diagnostic biomarker toolbox?

A

reliable biomarkers to monitor synaptic and dendritic function and loss directly

44
Q

What is Neurogranin?

A

dendritic protein expressed in the cortex and hippocampus with an important role in long‐term potentiation.

45
Q

Where is Neurogranin expression markedly reduced?

A
  1. Hippocampus
  2. Frontal cortex in AD

indicating loss of post-synaptic element

in AD

46
Q

What does measurement of neurogranin in CSF serve?

A

Biomarker for dendritic instability and synaptic degeneration

47
Q

What does meta analyses studies look at?

A

various AD cohorts and collate all the data that’s been found correlating the biomarker to AD

48
Q

What are biomarkers with the best performance?

A

Core CSF biomarkers

49
Q

What is strongly associated with AD?

A

Neurofilament light chain (NFL)

50
Q

What was moderately associated with AD?

A
  1. neuron specific enolase (NSE),
  2. visinin-like protein 1 (VLP-1),
  3. heart fatty acid binding protein (HFABP)
  4. glial activation protein YKL-40
51
Q

What should be used in clinical practice and clinical research?

A
  1. T-tau, P-tau, Aβ42 and NFL

2. Due to their consistency

52
Q

What is the most validated of AD?

A

CSF biomarkers

53
Q

What are advantages to CSF?

A
  1. Highly sensitive and specific - Not separated from the brain via BBB
  2. Can correlate with Alzheimer’s disease directly
  3. Can detect Alzheimer’s disease progression
54
Q

What are disadvantage to CSF?

A
  1. Invasive and painful procedure via lumbar puncture

2. Irreproducible diagnosis due to sample storage and transportation

55
Q

What makes an ideal for biomarker investigation?

A

Easier sampling of the blood plasma

56
Q

What has met with little success?

A

Plasma biomarkers

57
Q

What makes plasma biomarkers a much easier biomarker method?

A

Easier collection

58
Q

Whatmight occur due to different analytical methodologies utilised in various laboratories, different choice of anticoagulant and depletion strategy and storage related problems in blood-based biomarker?

A
  1. Irreproducibility
59
Q

What are biomarkers for Blood-based biomarkers for AD?

A
  1. CDH

2. a-2m

60
Q

What is the most popular plasma peptide utilised for biomarker reseacher?

A

AB

the fundamental element of senile plaques in brain of Alzheimer’s disease patients

61
Q

What are Ambiguous results probably explained by?

A

that plasma Aβis derived from peripheral tissues and may not reflect brain Aβproduction

62
Q

What can result in epitope masking?

A

the hydrophobic nature of Aβ makes the peptide bind to plasma proteins

63
Q

What did blood tests find?

A

Toxic Alzheimer’s proteins

64
Q

What did they term ab40, ab42 and APP fragment?

A
  1. app699-711

2. Based on its amino acid composition

65
Q

What are advantages for blood?

A
  1. Non-invasive
  2. Samples are easily accessible
  3. Cost effective and routine
  4. ~500ml of CSF absorbed into blood each day
66
Q

What are disadvantage of Blood?

A
  1. Less sensitive and specific than CSF (e.g. epitope masking)
  2. Less correlation with Alzheimer’s disease than CSF